Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lysulin is a private U.S. consumer health company focused on nutritional supplements for blood sugar support, A1c management, and insulin function. Founded by Dexcom founder John Burd, the company markets commercially available products formulated with lysine, zinc, and vitamin C for people with diabetes, prediabetes, or elevated blood sugar concerns. Its portfolio includes capsules, powder, liquid, chewables, and a weight-loss shake, and it also sells home A1c testing kits through its direct-to-consumer channel. Lysulin appears to operate as a commercial supplement brand rather than a drug-development biotech, with no disclosed clinical-stage therapeutic pipeline typical of pharma or biotech companies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Lysulin.